Additional FDA approval for KEYTRUDA® announced
On January 6th, 2022
Merck announces that the FDA has approved KEYTRUDA® (pembrolizumab) Injection 100 mg for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following complete resection. • PD-L1 diagnostic testing is not required prior to initiating treatment with KEYTRUDA in these patients. Before prescribing KEYTRUDA® (pembrolizumab), please read the Prescribing Information. The Medication Guide also is available.
Merck announces that the FDA has approved KEYTRUDA® (pembrolizumab) Injection 100 mg for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following complete resection. • PD-L1 diagnostic testing is not required prior to initiating treatment with KEYTRUDA in these patients. Before prescribing KEYTRUDA® (pembrolizumab), please read the Prescribing Information. The Medication Guide also is available.
No comments have been posted yet.